Status:
COMPLETED
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolaemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment
Eligibility Criteria
Inclusion
- Male or female 18 or over.
- A history of CHD or clinical evidence of atherosclerosis (diabetic or non-diabetic) or a CHD risk equivalent (10-year risk score \> 20% for CHD as described in NCEP ATP III guidelines1.
Exclusion
- History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin
- Pregnancy
- History of homozygous familial hypercholesterolaemia.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
August 1 2004
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00329173
Start Date
November 1 2003
End Date
August 1 2004
Last Update
March 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.